Education
- BA in Biology, Stanford University, Stanford, CA, 1966
- MD, University of California at Los Angeles, 1970
- Internal Medicine, Endocrinology/Metabolism, Harbor-UCLA Medical Center, Torrance CA, 1970-1975
Research Interests
Dr. Greenway's area of interest is developing obesity treatments including diets,
herbal supplements, medical foods, devices, obesity surgery and obesity drug development.
His laboratory uses human fat cells in culture to discover food components with pharmacological
properties for using food as medicine. He directs the outpatient research clinic.
Core: Clinical Trials Unit
Selected Publications
- Naringenin and β-carotene convert human white adipocytes to a beige phenotype and
elevate hormone- stimulated lipolysis. Coulter AA, Greenway FL, Zhang D, Ghosh S, Coulter CR, James SL, He Y, Cusimano LA, Rebello CJ. Front Endocrinol
(Lausanne). 2023 Apr 17;14:1148954. doi: 10.3389/fendo.2023.1148954. eCollection 2023.PMID: 37143734
- Orlistat mouth rinse: Using the tongue to deliver antiobesity medication in a double-blind
randomized crossover pilot trial. Primeaux SD, Dubin R, Greenway FL. Diabetes Obes Metab. 2023 Aug;25(8):2236-2242. doi: 10.1111/dom.15101. Epub 2023 May
3.PMID: 37132340
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults
With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, Sørrig R, Wadden TA, Wizert A, Garvey WT; STEP
8 Investigators. 2022 Jan 11;327(2):138-150. doi: 10.1001/jama.2021.23619.PMID: 35015037
- MLR-1023 Treatment in Mice and Humans Induces a Thermogenic Program, and Menthol Potentiates
the Effect. Rebello CJ, Coulter AA, Reaume AG, Cong W, Cusimano LA, Greenway FL. Pharmaceuticals (Basel). 2021 Nov 22;14(11):1196. doi: 10.3390/ph14111196.PMID: 34832978
- Mechanism for the Increase in Human Growth Hormone with Administration of a Novel
Test Supplement and Results Indicating Improved Physical Fitness and Sleep Efficiency. Heaton AL, Kelly C, Rood J, Tam CS, Greenway FL.J Med Food. 2021 Jun;24(6):653-659. doi: 10.1089/jmf.2020.0109. Epub 2020 Oct 8.PMID: 3303039
- Safety and pharmacokinetics of naringenin: A randomized, controlled, single-ascending-dose
clinical trial. Rebello CJ, Beyl RA, Lertora JJL, Greenway FL, Ravussin E, Ribnicky DM, Poulev A, Kennedy BJ, Castro HF, Campagna SR, Coulter AA,
Redman LM.Diabetes Obes Metab. 2020 Jan;22(1):91-98. doi: 10.1111/dom.13868. Epub
2019 Sep 30.PMID: 31468636
- A Randomized, Double-Blind, Placebo-Controlled Study of Gelesis100: A Novel Nonsystemic
Oral Hydrogel for Weight Loss. Greenway FL, Aronne LJ, Raben A, Astrup A, Apovian CM, Hill JO, Kaplan LM, Fujioka K, Matejkova
E, Svacina S, Luzi L, Gnessi L, Navas-Carretero S, Alfredo Martinez J, Still CD, Sannino
A, Saponaro C, Demitri C, Urban LE, Leider H, Chiquette E, Ron ES, Zohar Y, Heshmati
HM.Obesity (Silver Spring). 2019 Feb;27(2):205-216. doi: 10.1002/oby.22347. Epub 2018
Nov 13.PMID: 30421844
- Polytetrafluoroethylene Ingestion as a Way to Increase Food Volume and Hence Satiety
Without Increasing Calorie Content. Naftalovich R, Naftalovich D, Greenway FL. J Diabetes Sci Technol. 2016 Jun 28;10(4):971-6. doi: 10.1177/1932296815626726. Print
2016 Jul.PMID: 26810925
- Using Caenorhabditis elegans as a Model for Obesity Pharmacology Development. Zheng J, Vasselli JR, King JF, King ML, We W, Fitzpatrick Z, Johnson WD, Finley JW,
Martin RJ, Keenan MJ, Enright FM, Greenway FL. Am J Ther. 2016 Nov/Dec;23(6):e1363-e1370. doi: 10.1097/MJT.0000000000000061.PMID: 24786852
- Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E; COR-I Study Group. 2010 Aug 21;376(9741):595-605. doi: 10.1016/S0140-6736(10)60888-4. Epub 2010 Jul 29.PMID: 20673995
